Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar Interchangeable Exclusivity Guidance Still Planned Despite Memo Release, US FDA Says

Nov 28 2023

• By Derrick Gingery

compass — Many concepts in the memo could be reflected in upcoming guidance on biosimilar first interchangeable exclusivity. • Source: Shutterstock

Related Content

US FDA Outlines Biosimilar First Interchangeability Policy … In A Memo

Nov 13 2023

In Swift Challenge To Orange Book Patent Listings, Federal Trade Commission Fills FDA Ministerial Gap

Nov 08 2023

Interchangeable Exclusivity: Pfizer To Rival Boehringer On Humira Biosimilar After US FDA Decision

Oct 10 2023

Biosimilars: US FDA Developing Guidance For First Interchangeable Exclusivity

Nov 18 2020

Related Companies

Boehringer Ingelheim GmbH

AbbVie Inc.

Additional Topics

United States Biosimilars Market Access Policy BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window